SIBIONICS
Innovating for You: Revolutionizing Diabetes Care with Every Step.
Since our founding in 2015, SIBIONICS has been at the forefront of transforming diabetes management. Born from a commitment to innovation and a profound understanding of the everyday challenges faced by those with diabetes, we've consistently aimed to redefine the landscape of Continuous Glucose Monitoring (CGM) systems. By merging cutting-edge technology with designs centered around the user, we deliver solutions that not only meet needs but exceed expectations.
Today, with over 1,000,000 users across the globe, SIBIONICS stands as a beacon of reliability and innovation in diabetes care. Our global presence is a testament to the effectiveness of our CGM solutions and our dedication to making a significant, positive impact worldwide.
Looking ahead, SIBIONICS is committed to continuing our legacy of innovation. We're not just keeping pace; we're setting the pace—constantly pushing the boundaries of what's possible in CGM technology and striving for excellence with each new product we introduce.
Innoveer onderliggende technologieën ten behoeve van de volksgezondheid
We richten ons op de behoeften op het gebied van gezondheidsbeheer van de meest uitgebreide bevolking, en geven ook om ziektediagnose en therapeutische regimes van populaties met zeldzame ziekten. We hebben een uitstekend team van wetenschappers geïntegreerd om baanbrekende wetenschappelijke onderzoeksresultaten voortdurend om te zetten in medische producten en de volksgezondheid te dienen.
Technologische inzichten in het onbekende wekken potentieel voor het leven
Op basis van de behoeften van patiënten introduceren we biochemie, chipontwerp, kunstmatige intelligentie, automatisering en andere technologieën om inzicht te krijgen in de onbekende gebieden van gezondheidsgegevens en mensen te helpen veranderingen door te voeren in de richting van een betere levenskwaliteit
Certificaten
Wij zijn toegewijd aan het helpen van klanten bij het verbeteren van de productkwaliteit en het aanpakken van uitdagingen.
Mijlpalen en productaanbod
2023
The GS1 CGM system received the CE mark for entering the European market.
2021
The continuous glucose monitoring system (CGM) was submitted to National Medical Products Administration for registration and was approved. The practicing license of Yinchuan Sibionics Internet Hospital was approved.
2020
AI-DR was approved as the first Class III medical device for AI-assisted fundus disease diagnosis software in China. Sibionics was certified as National High-tech Enterprise.
2019
Fundus camera obtained the registration certificate for Class II medical device. R&D of capsule endoscopy project was started.
2016
R&D of continuous glucose monitoring system (CGM) was started. R&D of diabetic retinopathy AI-assisted diagnosis software (AI-DR) was started.
2015
Sibionics was established, and American R&D Center was established. R&D of artificial retina project was started.
